CDMO News
Microbix Expands Kinlytic Urokinase Reach with CDMO Agreement
Microbix Biosystems, a Canadian biotech company, has announced a significant step forward in the production of Kinlytic urokinase, a biologic drug used for dissolving blood clots. The company’s financing and commercialisation partner, Sequel Pharma LLC, has executed an agreement with
15 March 2024